🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs
676

Quick answer

Neurology & CNS: NovaPharmaNews indexes 676 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Page 5 of 15

  1. Xanomeline and Trospium Chloride Capsules

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  2. Zonisamide

    Eisai Co.,

    Epilepsy

    phase 3 small molecule completed

    1 trial

  3. apomorphine infusion

    SUPERNUS PHARMACEUTICALS, INC.

    Idiopathic Parkinson's Disease

    phase 3 small molecule active

    1 trial

  4. bapineuzumab

    Pfizer

    Alzheimer Disease

    phase 3 small molecule terminated

    1 trial

  5. brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  6. brivaracetam, brivaracetam, brivaracetam, brivaracetam

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy, Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  7. copolymer 1

    Ultragenyx UK Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  8. dimethyl fumarate

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  9. gabapentin

    Pfizer

    Epilepsies, Partial

    phase 3 small molecule completed

    1 trial

  10. immune globulin

    Ultragenyx UK Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  11. lamotrigine, 300 mg/day

    GlaxoSmithKline

    Epilepsy, Partial

    phase 3 small molecule completed

    1 trial

  12. mannitol and microcrystalline cellulose, Tolebrutinib

    Genzyme Europe B.V.

    Primary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  13. masitinib, Placebo to 200mg masitinib, Placebo to 100mg masitinib, masitinib

    AB Science

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  14. mifepristone

    CORCEPT THERAPEUTICS INC

    Psychotic Depression

    phase 3 small molecule terminated

    1 trial

  15. perampanel

    Eisai Co.,

    Epilepsy

    phase 3 small molecule completed

    2 trials

  16. pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    1 trial

  17. placebo

    Pfizer

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  18. ublituximab

    TG THERAPEUTICS, INC.

    relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  19. ublituximab, DEXAMETHASONE, PARACETAMOL, GADOBUTROL, ublituximab placebo, DIPHENHYDRAMINE, CETIRIZINE, METHYLPREDNISOLONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  20. vormatrogine

    Chongqing Precision Biotech Co., Ltd

    Epilepsy, Tonic-Clonic

    phase 3 small molecule active

    1 trial

  21. 0.9% sodium chloride, GADOTERIC ACID

    Eli Lilly Co.

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  22. 00 mg/mL Concentrate for solution for infusion, VHB937

    Novartis Pharmaceuticals

    Alzheimer’s disease

    phase 2 small molecule active

    1 trial

  23. 18F-92

    The First People's Hospital of Lianyungang

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  24. 18FMC225_FPG

    Fondazione Telethon ETS

    depression

    phase 2 small molecule active

    1 trial

  25. 5-(1-(2-[18F] fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen

    Disc Medicine

    Alzheimers Disease, sporadic Cerebral Amyloid Angiopathy, Parkinson

    phase 2 small molecule active

    1 trial

  26. A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 other active

    1 trial

  27. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 2 other active

    1 trial

  28. A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS

    Pari Pharma GmbH

    Multiple sclerosis

    phase 2 other active

    1 trial

  29. ABBV-552

    AbbVie

    Alzheimer's Disease (AD)

    phase 2 small molecule completed

    1 trial

  30. ACP-103

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  31. ACP-104

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  32. ACT-1004-1239 matching placebo

    Lacuna Pharma Pty Ltd

    Progressive multiple sclerosis (MS)

    phase 2 small molecule active

    1 trial

  33. ADX48621

    Addex Therapeutics

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  34. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  35. AMBROXOL , Microcrystalline cellulose

    Disc Medicine

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  36. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  37. ARICEPT 10mg comprimidos recubiertos con película

    The George Institute

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  38. ARO-MAPT-SC

    Arrowhead Pharmaceuticals Ireland Limited

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  39. ATA188

    Evidence Based Cataract Study Group

    Primary Progressive Multiple Sclerosis

    phase 2 mab terminated

    1 trial

  40. AV-101

    Vistagen Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  41. AXS-05

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  42. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule terminated

    1 trial

  43. Active Treatment- CT1812 100 mg

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  44. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  45. Amiloride

    United Therapeutics Europe Ltd

    Secondary Progressive Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  46. Amyvid 1900 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, 0.9% (w/v) sodium chloride (Normal Saline), VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  47. Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection

    Acumen Pharmaceuticals

    Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

    phase 2 small molecule active

    1 trial

  48. Aplindore

    LIGAND PHARMACEUTICALS INC

    Early Stage Parkinson's Disease

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

676 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.